OTCMKTS:NIMU

Non-Invasive Monitoring Systems Competitors

$0.03
0.00 (0.00 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.03
Now: $0.03
$0.03
50-Day Range
$0.03
MA: $0.04
$0.06
52-Week Range
$0.02
Now: $0.03
$0.07
Volume400 shs
Average Volume16,568 shs
Market Capitalization$2.69 million
P/E RatioN/A
Dividend YieldN/A
Beta0.23

Competitors

Non-Invasive Monitoring Systems (OTCMKTS:NIMU) Vs. GTHP, RSLSD, MAGAA, NXNN, ARDMQ, and IMRSQ

Should you be buying NIMU stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Non-Invasive Monitoring Systems, including Guided Therapeutics (GTHP), ReShape Lifesciences (RSLSD), Magna-Lab (MAGAA), Nexeon MedSystems (NXNN), Aradigm (ARDMQ), and IMRIS (IMRSQ).

Non-Invasive Monitoring Systems (OTCMKTS:NIMU) and Guided Therapeutics (OTCMKTS:GTHP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Earnings and Valuation

This table compares Non-Invasive Monitoring Systems and Guided Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Non-Invasive Monitoring SystemsN/AN/A$-160,000.00N/AN/A
Guided Therapeutics$40,000.00265.25$-1,920,000.00N/AN/A

Non-Invasive Monitoring Systems has higher earnings, but lower revenue than Guided Therapeutics.

Profitability

This table compares Non-Invasive Monitoring Systems and Guided Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Non-Invasive Monitoring SystemsN/A-2,509.09%-80.19%
Guided TherapeuticsN/A-29.31%502.80%

Analyst Ratings

This is a breakdown of current recommendations for Non-Invasive Monitoring Systems and Guided Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Non-Invasive Monitoring Systems0000N/A
Guided Therapeutics0000N/A

Risk and Volatility

Non-Invasive Monitoring Systems has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Guided Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Summary

Guided Therapeutics beats Non-Invasive Monitoring Systems on 4 of the 5 factors compared between the two stocks.

Non-Invasive Monitoring Systems (OTCMKTS:NIMU) and ReShape Lifesciences (OTCMKTS:RSLSD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Earnings and Valuation

This table compares Non-Invasive Monitoring Systems and ReShape Lifesciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Non-Invasive Monitoring SystemsN/AN/A$-160,000.00N/AN/A
ReShape Lifesciences$610,000.003.12$-81,150,000.00N/AN/A

Non-Invasive Monitoring Systems has higher earnings, but lower revenue than ReShape Lifesciences.

Profitability

This table compares Non-Invasive Monitoring Systems and ReShape Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Non-Invasive Monitoring SystemsN/A-2,509.09%-80.19%
ReShape Lifesciences-668.58%-163.22%-52.10%

Analyst Ratings

This is a breakdown of current recommendations for Non-Invasive Monitoring Systems and ReShape Lifesciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Non-Invasive Monitoring Systems0000N/A
ReShape Lifesciences0000N/A

Risk and Volatility

Non-Invasive Monitoring Systems has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.

Summary

ReShape Lifesciences beats Non-Invasive Monitoring Systems on 4 of the 6 factors compared between the two stocks.

Non-Invasive Monitoring Systems (OTCMKTS:NIMU) and Magna-Lab (OTCMKTS:MAGAA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Earnings and Valuation

This table compares Non-Invasive Monitoring Systems and Magna-Lab's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Non-Invasive Monitoring SystemsN/AN/A$-160,000.00N/AN/A
Magna-LabN/AN/A$-130,000.00N/AN/A

Profitability

This table compares Non-Invasive Monitoring Systems and Magna-Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Non-Invasive Monitoring SystemsN/A-2,509.09%-80.19%
Magna-LabN/A-12.32%42,399.99%

Analyst Ratings

This is a breakdown of current recommendations for Non-Invasive Monitoring Systems and Magna-Lab, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Non-Invasive Monitoring Systems0000N/A
Magna-Lab0000N/A

Risk and Volatility

Non-Invasive Monitoring Systems has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Magna-Lab has a beta of 5.2, meaning that its share price is 420% more volatile than the S&P 500.

Summary

Magna-Lab beats Non-Invasive Monitoring Systems on 4 of the 4 factors compared between the two stocks.

Non-Invasive Monitoring Systems (OTCMKTS:NIMU) and Nexeon MedSystems (OTCMKTS:NXNN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Earnings and Valuation

This table compares Non-Invasive Monitoring Systems and Nexeon MedSystems' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Non-Invasive Monitoring SystemsN/AN/A$-160,000.00N/AN/A
Nexeon MedSystemsN/AN/AN/AN/AN/A

Profitability

This table compares Non-Invasive Monitoring Systems and Nexeon MedSystems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Non-Invasive Monitoring SystemsN/A-2,509.09%-80.19%
Nexeon MedSystemsN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations for Non-Invasive Monitoring Systems and Nexeon MedSystems, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Non-Invasive Monitoring Systems0000N/A
Nexeon MedSystems0000N/A

Risk and Volatility

Non-Invasive Monitoring Systems has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Nexeon MedSystems has a beta of 12.71, meaning that its share price is 1,171% more volatile than the S&P 500.

Summary

Nexeon MedSystems beats Non-Invasive Monitoring Systems on 3 of the 3 factors compared between the two stocks.

Non-Invasive Monitoring Systems (OTCMKTS:NIMU) and Aradigm (OTCMKTS:ARDMQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current recommendations for Non-Invasive Monitoring Systems and Aradigm, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Non-Invasive Monitoring Systems0000N/A
Aradigm0000N/A

Earnings and Valuation

This table compares Non-Invasive Monitoring Systems and Aradigm's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Non-Invasive Monitoring SystemsN/AN/A$-160,000.00N/AN/A
AradigmN/AN/AN/AN/AN/A

Profitability

This table compares Non-Invasive Monitoring Systems and Aradigm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Non-Invasive Monitoring SystemsN/A-2,509.09%-80.19%
AradigmN/AN/AN/A

Risk and Volatility

Non-Invasive Monitoring Systems has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Aradigm has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500.

Summary

Aradigm beats Non-Invasive Monitoring Systems on 3 of the 3 factors compared between the two stocks.

IMRIS (OTCMKTS:IMRSQ) and Non-Invasive Monitoring Systems (OTCMKTS:NIMU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings for IMRIS and Non-Invasive Monitoring Systems, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMRIS0000N/A
Non-Invasive Monitoring Systems0000N/A

Earnings & Valuation

This table compares IMRIS and Non-Invasive Monitoring Systems' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMRISN/AN/AN/AN/AN/A
Non-Invasive Monitoring SystemsN/AN/A$-160,000.00N/AN/A

Profitability

This table compares IMRIS and Non-Invasive Monitoring Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMRISN/AN/AN/A
Non-Invasive Monitoring SystemsN/A-2,509.09%-80.19%

Risk & Volatility

IMRIS has a beta of -10.69, meaning that its share price is 1,169% less volatile than the S&P 500. Comparatively, Non-Invasive Monitoring Systems has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500.

Summary

IMRIS beats Non-Invasive Monitoring Systems on 2 of the 3 factors compared between the two stocks.


Non-Invasive Monitoring Systems Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
GTHP
Guided Therapeutics
0.3$0.81flat$10.41 million$40,000.00-3.35High Trading Volume
Gap Down
RSLSD
ReShape Lifesciences
0.5$5.37flat$1.94 million$610,000.000.00High Trading Volume
MAGAA
Magna-Lab
0.7$1.02flat$1.20 millionN/A5.67
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.55flat$1.12 millionN/A0.00
ARDMQ
Aradigm
0.0$0.05flat$764,000.00N/A0.00
IMRIS logo
IMRSQ
IMRIS
0.5$0.01flat$447,000.00N/A0.00
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.03flat$356,000.00N/A0.00
ULGX
Urologix
0.6$0.01flat$192,000.00N/A0.00
SCIE
SpectraScience
0.5$0.00flat$177,000.00N/A0.00
AKSY
Aksys
0.0$0.00flat$0.00N/A0.00
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.34flat$0.00$9.40 million-5.67Gap Up
HRTT
Heart Tronics
0.0$0.15flat$0.00N/A0.00
IVVI
Ivivi Technologies
0.0$0.00flat$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00flat$0.00N/A0.00
PECN
Photoelectron
0.2$0.03flat$0.00N/A0.00
Trimedyne logo
TMED
Trimedyne
0.4$4.25flat$0.00$5.57 million0.00
XCRP
Xcorporeal
0.0$0.00flat$0.00N/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.